Article info

Original research
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Authors

  1. Correspondence to Dr Sophie Postel-Vinay; sophie.postel-vinay{at}gustaveroussy.fr
View Full Text

Citation

Postel-Vinay S, Lam VK, Ros W, et al
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Publication history

  • Accepted February 21, 2023
  • First published March 16, 2023.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.